Hot Asian Companies To Watch In Right Now

Hot Asian Companies To Watch In Right Now: DexCom Inc.(DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company offers FDA approved SEVEN, which includes a disposable sensor that can be inserted by a patient and used continuously for up to seven days; a transmitter; and a small handheld receiver. Its SEVEN system also received CE Mark approval for commercialization in the European Union and the countries in Asia and Latin America that recognize the CE Mark. The company also provides the SEVEN PLUS, which incorporates additional user interface and algorithm enhancements that are intended to make its glucose monitoring function customizable. Its SEVEN PLUS has FDA and CE Mark approvals. DexCom has a collaboration agreement with Edwards Lifesciences LLC to develop products for conti nuously monitoring blood glucose levels in patients hospitalized for various conditions. It also has development agreement with Insulet Corporation to integrate its continuous glucose monitoring technology into Insulet?s wireless, handheld OmniPod System Personal Diabetes Manager; and a joint development agreement with Animas Corporation to integrate its continuous glucose monitoring technology into Animas insulin pumps. The company was founded in 1999 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Motley Fool Staff]

  If we hope to halt or reverse those numbers, we'll need to approach patient care more holistically, and that could mean looking beyond drug therapies toward Dexcom's (NASDAQ: DXCM  ) continuous glucose monitoring sensors. Those sensors track and trend glucose levels, and alert patients when levels reach certain levels. By more accurately monitoring and treating these levels, patie! nts might delay disease progression. That, in fact, could already be happening. Dexcom's sales jumped 60% in the past year to $68 million in the third quarter. But there's much work still to be done. Industry watchers estimate less than half of type 1 diabeticsand an even smaller percentage of type 2 patientsuse monitors or insulin pumps to manage their disease.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-asian-companies-to-watch-in-right-now.html